Bicycle Therapeutics plc

(NASDAQ:BCYC)

Latest On Bicycle Therapeutics plc (BCYC):

Date/Time Type Description Signal Details
2023-05-14 14:15 ESTNewsBicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs YetN/A
2023-05-10 11:38 ESTNewsBicycle stock jumps on pact with Bayer to develop radiopharmaceuticals for cancerN/A
2023-05-04 21:13 ESTNewsBicycle Therapeutics GAAP EPS of -$1.30, revenue of $4.89MN/A
2023-03-28 17:17 ESTNewsBicycle stock pops on cancer drug discovery pact with Novartis, gets $50M upfrontN/A
2023-02-28 15:09 ESTNewsBicycle Therapeutics GAAP EPS of -$1.01 beats by $0.05, revenue of $3.19M misses by $0.56MN/A
2023-02-14 18:15 ESTNewsBicycle Therapeutics posts Phase 1 data for cancer candidateN/A
2023-01-04 15:09 ESTNewsBicycle Therapeutics adds 10% on FDA’s fast track tag for bladder cancer therapyN/A
2022-11-03 21:35 ESTNewsBicycle Therapeutics GAAP EPS of -$0.96 misses by $0.05, revenue of $3.04M misses by $2.54MN/A
2022-10-08 01:53 ESTNewsBicycle Therapeutics: Exploring An Intriguing Developmental PlatformN/A
2022-09-01 00:39 ESTNewsBicycle Therapeutics initiated Outperform at Cowen citing drug platformN/A
2022-08-04 22:13 ESTNewsBicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0.69MN/A
2022-07-12 21:29 ESTNewsBicycle to get $10M as Genentech uses option for new program under cancer drug collaborationN/A
2022-07-06 01:28 ESTNewsBicycle Therapeutics: Promising Early-Stage Cancer Drug DeveloperN/A
2022-05-05 19:05 ESTNewsBicycle Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $3.86M misses by $0.55MN/A
2022-04-17 04:20 ESTNewsBicycle Therapeutics: Trying To Catch This Falling KnifeN/A
2022-04-11 15:59 ESTNewsBicycle Therapeutics down 33% after rising sharply on Friday on bladder cancer dataN/A
2022-04-11 15:59 ESTNewsBicycle Therapeutics presents at AACR Annual Meeting 2022 - SlideshowN/A
2022-04-09 02:28 ESTNewsBicycle Therapeutics gains on early-stage data for oncology asset in bladder cancerN/A
2022-03-27 00:04 ESTNewsBicycle Therapeutics: A Buy Ahead Of AACR PresentationN/A
2022-03-01 19:32 ESTNewsBicycle Therapeutics GAAP EPS of -$0.63 beats by $0.01, revenue of $3.77M misses by $1.11MN/A
2022-02-28 05:43 ESTNewsBicycle Therapeutics: An Oncology Play With Big PotentialN/A
2022-01-05 15:44 ESTNewsBicycle Therapeutics COO transitions to CTO; provides clinical program updatesN/A
2021-11-10 00:38 ESTNewsBicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is NextN/A
2021-11-04 23:17 ESTNewsBicycle Therapeutics gets dosing underway in early-stage BT7480 cancer trialN/A
2021-11-04 23:17 ESTNewsBicycle Therapeutics EPS beats by $0.03, misses on revenueN/A
2021-10-26 09:10 ESTNewsGenentech exercises option for new immuno-oncology program with Bicycle TherapeuticsN/A
2021-10-13 15:17 ESTNewsBicycle Therapeutics prices upsized ADS offering at $54N/A
2021-10-12 18:51 ESTNewsBicycle Therapeutics falls 5% on proposed ADS offeringN/A
2021-10-08 21:15 ESTNewsBicycle Therapeutics draws higher price targets from analysts after cancer study dataN/A
2021-10-08 01:35 ESTNewsBicycle's shares rise as early-stage candidate shows preliminary anti-tumor activity (updated)N/A
2021-08-25 11:00 ESTNewsBicycle Therapeutics: Scaffolding Short Linear Peptides Into BicyclesN/A
2021-08-05 20:10 ESTNewsBicycle Therapeutics EPS misses by $0.02, misses on revenueN/A
2021-07-22 16:37 ESTNewsIonis inks licensing deal with Bicycle Therapeutics to advance LICA technologyN/A
2021-05-07 01:50 ESTNewsBicycle Therapeutics EPS misses by $0.05, beats on revenueN/A
2021-03-18 11:26 ESTAnalyst RatingThe Analyst Target Price has increased from $34.88 to $36.75.Buy
2021-03-13 18:12 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 13:59 ESTEarnings EstimateAn EPS average of -$3.34 is estimated for the 2022 year.Sell
2021-03-12 13:59 ESTEarnings EstimateAn EPS average of -$0.59 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 21:22 ESTNewsBicycle Therapeutics EPS misses by $0.32, beats on revenueN/A
2021-01-21 14:38 ESTAnalyst RatingThe Analyst Target Price has increased from $31.38 to $34.88.Buy
2021-01-18 06:16 ESTAnalyst RatingThe Analyst Target Price has increased from $27.75 to $31.38.Buy
2021-01-14 14:35 ESTNewsBicycle Therapeutics gives out pipeline update, shares riseN/A
2020-12-04 19:08 ESTFinancialsCompany financials have been released.Neutral
2020-12-04 10:53 ESTAnalyst RatingThe Analyst Target Price has increased from $27.38 to $27.75.Buy
2020-12-02 13:28 ESTNewsBicycle Therapeutics settles IP dispute with PepscanN/A
2020-11-27 00:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 15:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $27.75 to $27.38.Neutral
2020-11-06 23:03 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 10:34 ESTEarnings EstimateAn EPS average of -$0.54 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-06 10:34 ESTAnalyst RatingThe Analyst Target Price has increased from $25.5 to $27.75.Buy

About Bicycle Therapeutics plc (BCYC):

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BCYC Quotes by TradingView

See Advanced Chart

General

  • Name Bicycle Therapeutics plc
  • Symbol BCYC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 87
  • Fiscal Year EndDecember
  • IPO Date2019-05-23
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.bicycletherapeutics.com
View More

Valuation

  • Trailing PE 1839
  • Price/Sales (Trailing 12 Mt.) 52
  • Price/Book (Most Recent Quarter) 6.83
  • Enterprise Value Revenue 51.14
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.92
  • Next Year EPS Estimate -$3.38
  • Next Quarter EPS Estimate -$0.60
  • Operating Margin -500%
  • Return on Assets -24%
  • Return on Equity -54%
  • Revenue 10.39 million
  • Earnings Per Share -$14.16
  • Revenue Per Share $0.54
  • Gross Profit -22759000
  • Quarterly Earnings Growth -27.1%
View More

Highlights

  • Market Capitalization 618.36 million
  • EBITDA -24381000
  • PE Ratio -6.18
  • Analyst Target Price $36.75
  • Book Value Per Share $5.33
View More

Share Statistics

  • Shares Outstanding 23.09 million
  • Shares Float 14.83 million
  • % Held by Insiders 2990%
  • % Held by Institutions 42.85%
  • Shares Short 400080
  • Shares Short Prior Month 397139
  • Short Ratio 2.76
  • Short % of Shares Outstanding 2%
View More

Technicals

  • 52 Week High $33
  • 52 Week Low $10.5
  • 50 Day Moving Average 26.66
  • 200 Day Moving Average 21.57
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Bicycle Therapeutics plc (BCYC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Bicycle Therapeutics plc (BCYC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.83-$0.41-101.6%
2020-09-302020-11-05$N/A-$0.52-$0.531.89%
2020-06-302020-08-05$N/A-$0.67-$0.46-45.02%
2020-03-312020-05-07$N/A-$0.63-$0.38-64.36%
2019-12-312020-03-10$5.28 million-$0.25-$0.5251.62%
2019-09-302019-11-07$614000-$0.53-$0.7023.74%
2019-06-302019-08-08$1.52 million-$0.66-$0.62-6.45%
2019-03-312019-05-23$6.38 million-$0.49

Bicycle Therapeutics plc (BCYC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A N/A 6.65 million
Income Before Tax N/A N/A N/A N/A -4.54 million
Selling General Administrative N/A N/A N/A N/A 3.4 million
Gross Profit N/A N/A N/A N/A -1.37 million
Ebit N/A N/A N/A N/A -4.49 million
Operating Income N/A N/A N/A N/A -4.76 million
Income Tax Expense -56000 -465000 -97000 -107000 -138000
Total Revenue N/A N/A N/A N/A 5.28 million
Cost of Revenue N/A N/A N/A N/A 6.65 million
Total Other Income Expense Net N/A N/A N/A N/A N/A
Net Income From Continuing Operations N/A N/A N/A N/A -4.41 million
Net Income Applicable to Common Shares -17.43 million -10.14 million -12.12 million -11.32 million -4.41 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A -391000 -283000
Change to Liabilities -2.36 million -2.47 million 32.81 million -5.09 million -187000
Total Cash Flow from Investing Activities -95000 -301000 -320000 -391000 -283000
Net Borrowings 15 million N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A 122000 -811000
Change to Operating Activities 3.03 million 89000 -1.9 million 3.37 million -2.39 million
Change in Cash N/A N/A N/A -3.84 million -12.58 million
Total Cash from Operating Activities -9.99 million -12.35 million 21.16 million -4.92 million -10.89 million
Depreciation N/A N/A N/A 274000 243000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A -155000 109000
Other Cash Flow from Financing Activities -373000 N/A N/A N/A N/A
Change to Net Income 1.51 million 1.32 million 2.12 million 1.08 million 819000
Capital Expenditures N/A N/A N/A 391000 283000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A 47.47 million 17 million
Total Stockholder Equity N/A N/A N/A 81.81 million 93.2 million
Other Current Liabilities 10.34 million 7.19 million N/A 133000 67000
Total Assets N/A N/A N/A 129.28 million 110.19 million
Common Stock 266000 264000 228000 227000 227000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -151.56 million -134.13 million -123.99 million -111.87 million -100.55 million
Other Liabilities 27.63 million 28.39 million 29.75 million 30.22 million 6.92 million
Other Assets 1.82 million 2.4 million 2.27 million 1.87 million 1.7 million
Cash N/A N/A N/A 109.64 million 92.12 million
Total Current Liabilities 23.13 million 17.05 million N/A 16.2 million 8.82 million
Other Stockholder Equity -3.19 million -2.98 million -3.72 million -3.72 million -1.54 million
Property, Plant & Equipment 3.61 million 3.5 million 3.8 million 4.02 million 4.35 million
Total Current Assets 155.72 million 164.16 million N/A 123.39 million 104.15 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 95.46 million 109.55 million 71.03 million 81.81 million 93.2 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.37 million 2.06 million N/A 4.43 million 1.95 million

Bicycle Therapeutics plc (BCYC) Chart:

Bicycle Therapeutics plc (BCYC) News:

Below you will find a list of latest news for Bicycle Therapeutics plc (BCYC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bicycle Therapeutics plc (BCYC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-06-1810CALL0 00TRUE00
2026-06-1820CALL0 00TRUE00
2026-06-1830CALL0 0410.82TRUE00
2026-06-1840CALL0 5512.78TRUE00
2026-06-1850.1CALL74 177851.82FALSE-0.1-0.5
2026-06-1860.3CALL0 104079.02FALSE00
2026-06-1870CALL0 8146.25FALSE00
2026-06-1880CALL0 168690.73FALSE00
2026-06-1890CALL0 110716.03FALSE00
2026-06-18100CALL0 2294422.55FALSE00
2026-06-18110CALL0 11447.96FALSE00
2026-06-18120CALL0 3773.98FALSE00
2026-06-18130CALL0 0789.28FALSE00
2026-06-18140CALL0 2803.16FALSE00
2026-06-18150CALL0 0815.84FALSE00
2026-06-18160CALL0 0682.63FALSE00
2026-06-1810PUT0 00FALSE00
2026-06-1820PUT0 50FALSE00
2026-06-1830PUT0 689132.61FALSE00
2026-06-1840.1PUT13 357566.26FALSE-0.03-0.23
2026-06-1850.8PUT0 6030TRUE00
2026-06-1860PUT0 0300.59TRUE00
2026-06-1870PUT0 1134.28TRUE00
2026-06-1880PUT0 1161.14TRUE00
2026-06-1890PUT0 0183.65TRUE00
2026-06-18100PUT0 1178.67TRUE00
2026-06-18110PUT0 0220.15TRUE00
2026-06-18120PUT0 0209.26TRUE00
2026-06-18130PUT0 0222.36TRUE00
2026-06-18140PUT0 0234.34TRUE00
2026-06-18150PUT0 0245.37TRUE00
2026-06-18160PUT0 0283.86TRUE00
2026-07-1710CALL0 00TRUE00
2026-07-1722.5CALL0 10136.09TRUE00
2026-07-1730CALL0 0281.63TRUE00
2026-07-1740CALL0 0351.93TRUE00
2026-07-1750CALL0 0396.28FALSE00
2026-07-1760CALL0 0428.57FALSE00
2026-07-1770CALL0 0453.82FALSE00
2026-07-1780CALL0 0474.47FALSE00
2026-07-1790CALL0 0491.88FALSE00
2026-07-1710PUT0 00FALSE00
2026-07-1720PUT0 00FALSE00
2026-07-1730PUT0 0115.03FALSE00
2026-07-1740.25PUT0 26255.7FALSE00
2026-07-1750PUT0 0322.37TRUE00
2026-07-1760PUT0 0208.23TRUE00
2026-07-1770PUT0 081.97TRUE00
2026-07-1780PUT0 099.82TRUE00
2026-07-1790PUT0 0114.94TRUE00
2026-09-1810CALL0 00TRUE00
2026-09-1820CALL0 00TRUE00
2026-09-1830CALL0 52191.02TRUE00
2026-09-1840CALL0 0239.33TRUE00
2026-09-1850CALL0 17136.96FALSE00
2026-09-1860CALL0 13589.69FALSE00
2026-09-1870CALL0 0179.93FALSE00
2026-09-1880CALL0 0109.76FALSE00
2026-09-1890CALL0 0203.45FALSE00
2026-09-18100CALL0 1211.99FALSE00
2026-09-18110CALL0 0223.96FALSE00
2026-09-18120CALL0 1362.46FALSE00
2026-09-18130CALL0 119369.66FALSE00
2026-09-1810PUT0 00FALSE00
2026-09-1820PUT0 00FALSE00
2026-09-1830.1PUT0 192669.06FALSE00
2026-09-1840.35PUT0 88245.09FALSE00
2026-09-1851PUT0 24433.68TRUE00
2026-09-1860PUT0 0105.48TRUE00
2026-09-1870PUT0 068.54TRUE00
2026-09-1880PUT0 082.23TRUE00
2026-09-1890PUT0 093.79TRUE00
2026-09-18100PUT0 0103.84TRUE00
2026-09-18110PUT0 00TRUE00
2026-09-18120PUT0 0120.7TRUE00
2026-09-18130PUT0 0127.94TRUE00
2026-12-1810CALL0 0186.86TRUE00
2026-12-1820CALL0 00TRUE00
2026-12-1830CALL0 0142.14TRUE00
2026-12-1840CALL0 0178.8TRUE00
2026-12-1852.83CALL0 631111.37FALSE00
2026-12-1860CALL0 0218.48FALSE00
2026-12-1870CALL0 0231.52FALSE00
2026-12-1880.55CALL0 5242.18FALSE00
2026-12-1890CALL0 0251.15FALSE00
2026-12-18102.18CALL0 1127.07FALSE00
2026-12-1810PUT0 00FALSE00
2026-12-1820PUT0 1074.94FALSE00
2026-12-1830PUT0 095.04FALSE00
2026-12-1840PUT0 571.51FALSE00
2026-12-1850PUT0 0169.4TRUE00
2026-12-1860PUT0 0110.88TRUE00
2026-12-1870PUT0 069.36TRUE00
2026-12-1880PUT0 071.34TRUE00
2026-12-1890PUT0 074.98TRUE00
2026-12-18100PUT0 083.03TRUE00

Latest BCYC Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$13.335
Jun 13, 2022 7:59 PM EST200$13.335
Jun 13, 2022 7:59 PM EST17$13.33
Jun 13, 2022 7:59 PM EST975$13.3
Jun 13, 2022 7:59 PM EST200$13.36

Bicycle Therapeutics plc (BCYC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm
2020-06-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1761612/000000000020005156/0000000000-20-005156-index.htm
2020-09-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000089914020000427/0000899140-20-000427-index.htm
2020-07-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1761612/000092963820000753/0000929638-20-000753-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1761612/000104746920002601/0001047469-20-002601-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919060061/0001104659-19-060061-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919060805/0001104659-19-060805-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919062674/0001104659-19-062674-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919065673/0001104659-19-065673-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919075599/0001104659-19-075599-index.htm
2020-01-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920008696/0001104659-20-008696-index.htm
2020-02-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920010545/0001104659-20-010545-index.htm
2020-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920024459/0001104659-20-024459-index.htm
2020-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920027088/0001104659-20-027088-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920030969/0001104659-20-030969-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920031393/0001104659-20-031393-index.htm
2020-04-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920043974/0001104659-20-043974-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920057711/0001104659-20-057711-index.htm
2020-06-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1761612/000110465920070493/0001104659-20-070493-index.htm
2020-06-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1761612/000110465920072426/0001104659-20-072426-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm
2020-07-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920083108/0001104659-20-083108-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920090550/0001104659-20-090550-index.htm
2020-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920090870/0001104659-20-090870-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920110716/0001104659-20-110716-index.htm
2020-10-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1761612/000110465920111698/0001104659-20-111698-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920111705/0001104659-20-111705-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920121565/0001104659-20-121565-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051098/0001209191-19-051098-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051100/0001209191-19-051100-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051101/0001209191-19-051101-index.htm
2019-11-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119055217/0001209191-19-055217-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119061400/0001209191-19-061400-index.htm
2020-01-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001912/0001209191-20-001912-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001917/0001209191-20-001917-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001921/0001209191-20-001921-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001925/0001209191-20-001925-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001930/0001209191-20-001930-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001944/0001209191-20-001944-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001967/0001209191-20-001967-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001981/0001209191-20-001981-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001990/0001209191-20-001990-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002003/0001209191-20-002003-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002011/0001209191-20-002011-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002019/0001209191-20-002019-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120012510/0001209191-20-012510-index.htm
2020-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025811/0001209191-20-025811-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025812/0001209191-20-025812-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025813/0001209191-20-025813-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025816/0001209191-20-025816-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025817/0001209191-20-025817-index.htm
2020-08-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120047523/0001209191-20-047523-index.htm
2020-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120048252/0001209191-20-048252-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1761612/000138713120001831/0001387131-20-001831-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000138713120008376/0001387131-20-008376-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837019010277/0001558370-19-010277-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1761612/000155837020002278/0001558370-20-002278-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020005538/0001558370-20-005538-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020009277/0001558370-20-009277-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020012697/0001558370-20-012697-index.htm
2020-06-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1761612/999999999520001433/9999999995-20-001433-index.htm

Bicycle Therapeutics plc (BCYC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bicycle Therapeutics plc (BCYC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2990%
Institutional Ownership: 4285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-14Gregory Paul WinterDirectorBuy71,450.00163,927.00https://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm